Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 618

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

Open access
Bi, Kevin, He, Meng Xiao, Bakouny, Ziad, Kanodia, Abhay, Napolitano, Sara, Wu, Jingyi, Grimaldi, Grace, Braun, David A., Cuoco, Michael S., Mayorga, Angie, DelloStritto, Laura, Bouchard, Gabrielle, Steinharter, John, Tewari, Alok K., Vokes, Natalie I., Shannon, Erin, Sun, Maxine, Park, Jihye, Chang, Steven L., McGregor, Bradley A., Haq, Rizwan, Denize, Thomas, Signoretti, Sabina, Guerriero, Jennifer L., Vigneau, Sébastien, Rozenblatt-Rosen, Orit, Rotem, Asaf, Regev, Aviv, Choueiri, Toni K., Van Allen, Eliezer M.·2021·Cancer Cell

Abstract

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly understood. We characterize the single-cell transcriptomes of cancer and immune cells from metastatic RCC patients before or after ICB exposure. In responders, subsets of cytotoxic T cells express higher levels of co-inhibitory receptors and effector molecules. Macrophages from treated biopsies shift toward pro-inflammatory states in response to an interferon-rich microenvironment but also upregulate immunosuppressive markers. In cancer cells, we identify bifurcation into two subpopulations differing in angiogenic signaling and upregulation of immunosuppressive programs after ICB. Expression signatures for cancer cell subpopulations and immune evasion are associated with PBRM1 mutation and survival in primary and ICB-treated advanced RCC. Our findings demonstrate that ICB remodels the RCC microenvironment and modifies the interplay between cancer and immune cell populations critical for understanding response and resistance to ICB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.02.015

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 1

  1. Sergushichev, 2016, An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation, BioRxiv

Cited by

See all 618

Metadata

Authors
Bi, K., He, M. X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D. A., Cuoco, M. S., Mayorga, A., DelloStritto, L., Bouchard, G., Steinharter, J., Tewari, A. K., Vokes, N. I., Shannon, E., Sun, M., Park, J., Chang, S. L., McGregor, B. A., Haq, R., Denize, T., Signoretti, S., Guerriero, J. L., Vigneau, S., Rozenblatt-Rosen, O., Rotem, A., Regev, A., Choueiri, T. K., & Van Allen, E. M.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-05
Volume
39
Issue
5
Pages
649-661.e5
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3133932842
Cited by
618
References
68
FWCI
34.57
Type
journal article
Language
en
Update notices
erratum (2025-06-09)
Open access
hybrid
Licence
Funders
  • Congressionally Directed Medical Research Programs (KC170216, KC190130)
  • NCI Cancer Moonshot (R01 CA227388, T32 CA009172, U01 CA233100, T32 GM008313, U2C CA233195)
  • Harvard Medical School
  • National Institutes of Health
  • National Science Foundation (GRFP DGE1144152)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. https://app.cochat.ai/papers/10.1016/j.ccell.2021.02.015
The paper
Bi, K., He, M. X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D. A., Cuoco, M. S., Mayorga, A., DelloStritto, L., Bouchard, G., Steinharter, J., Tewari, A. K., Vokes, N. I., Shannon, E., Sun, M., Park, J., Chang, S. L., . . . Van Allen, E. M. (2021). Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.02.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.